Editas Medicine Demonstrates First Achievement of In Vivo Editing … – Nasdaq
|
Editas Medicine Demonstrates First Achievement of In Vivo Editing …
Nasdaq CAMBRIDGE, Mass., May 13, 2017– Editas Medicine, Inc., a leading genome editing company, today announced results from a pre-clinical study. |
